Literature DB >> 3283384

Trial of ibuprofen to prevent post-vasectomy complications.

A L Manson1.   

Abstract

Sperm granuloma and epididymitis remain 2 of the most common and incapacitating complications of vasectomy. A study was designed to evaluate the possibility of reducing these inflammatory complications with a prophylactic course of a nonsteroidal anti-inflammatory drug. Patients undergoing outpatient vasectomy were randomized into 2 groups. Group 1 received a prophylactic course of ibuprofen and group 2 received no medication. The ibuprofen was tolerated well and no adverse reactions were noted. There was no increase in postoperative bleeding or hematoma formation. There was no clinical benefit or decrease in complication rate in the ibuprofen-treated group.

Entities:  

Keywords:  Clinical Research; Comparative Studies; Diseases; Drugs--administraction and dosage; Economic Factors; Epididymitis; Family Planning; Genital Effects, Male; Male Sterilization; Research And Development; Research Methodology; Sterilization, Sexual; Studies; Technology; Treatment; Urogenital Effects; Vas Occlusion; Vasectomy--complications

Mesh:

Substances:

Year:  1988        PMID: 3283384     DOI: 10.1016/s0022-5347(17)42732-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Is vasectomy harmful to health?

Authors:  S W McDonald
Journal:  Br J Gen Pract       Date:  1997-06       Impact factor: 5.386

Review 2.  [Special pain conditions in urology. Summary, literature review and suggestions].

Authors:  A Klotz; O Moormann
Journal:  Urologe A       Date:  2009-10       Impact factor: 0.639

3.  Systematic Review and Meta-Analysis of the Association Between Non-Steroidal Anti-Inflammatory Drugs and Operative Bleeding in the Perioperative Period.

Authors:  Tasce Bongiovanni; Elizabeth Lancaster; Yeranuí Ledesma; Evans Whitaker; Michael A Steinman; Isabel Elaine Allen; Andrew Auerbach; Elizabeth Wick
Journal:  J Am Coll Surg       Date:  2021-01-27       Impact factor: 6.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.